Erratum: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (PLoS Pathogens (2016) 12:4 (e1005535) DOI: 10.1371/journal.ppat.1005535);Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Hill, Alison L ^a   Rosenbloom, Daniel I S ^b   Goldstein, Edward ^c   Hanhauser, Emily ^d   Kuritzkes, Daniel R ^d   Siliciano, Robert F ^e   Henrich, Timothy J ^f  

^a HARVARD UNIVERSITY   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE PROBABILITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BAYESIAN APPROACH; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LATENT RESERVOIR; MATHEMATICAL PARAMETERS; MATHEMATICAL PHENOMENA; MEDICATION COMPLIANCE; MODEL; POLYMERASE CHAIN REACTION; REAL TIME PREDICTION; REBOUND; RESERVOIR REDUCTION; SAMPLING; SENSITIVITY ANALYSIS; SIMULATION; UNCERTAINTY; VIROGENESIS; VIRUS LOAD; ADULT; BAYES THEOREM; DRUG EFFECTS; FEMALE; HIV INFECTIONS; MALE; THEORETICAL MODEL; VIROLOGY; VIRUS LATENCY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTI-HIV AGENTS; BAYES THEOREM; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL; VIRAL LOAD; VIRUS LATENCY;

EID: 84964826038     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005778     Document Type: Erratum

References (60)

1. Durand CM, Blankson JN, Siliciano RF, Developing strategies for HIV-1 eradication. Trends in Immunology. 2012;33(11):554–562. Available from: http://www.sciencedirect.com/science/article/pii/S1471490612001123. doi: 10.1016/j.it.2012.07.00122867874
2. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012Jul;487(7408):482–485. Available from: http://www.nature.com/nature/journal/v487/n7408/full/nature11286.html. doi: 10.1038/nature1128622837004
3. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. The Lancet HIV. 2014;1(1):e13–e21. Available from: http://www.sciencedirect.com/science/article/pii/S2352301814700141. doi: 10.1016/S2352-3018(14)70014-126423811
4. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1 Infected Adults on Antiretroviral Therapy. Clinical Infectious Diseases. 2014Mar;58(6):883–890. Available from: http://cid.oxfordjournals.org/content/58/6/883. doi: 10.1093/cid/cit81324336828
5. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, et al. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. PLoS Pathog. 2013May;9(5):e1003347. doi: 10.1371/journal.ppat.100334723671416
6. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, et al. Long-Term Reduction in Peripheral Blood HIV-1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Journal of Infectious Diseases. 2013Jun;207(11):1694–1702. Available from: http://jid.oxfordjournals.org/content/early/2013/02/28/infdis.jit086. doi: 10.1093/infdis/jit08623460751
7. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, et al. Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases. Annals of Internal Medicine. 2014Sep;161(5):319–327. doi: 10.7326/M14-102725047577
8. Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. The New England Journal of Medicine. 2015Feb;372(8):786–788. doi: 10.1056/NEJMc141393125693029
9. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication. AIDS. 2010Nov;24(18):2803–2808. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154092/. doi: 10.1097/QAD.0b013e328340a23920962613
10. Hill AL, Rosenbloom DIS, Fu F, Nowak MA, Siliciano RF, Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA. 2014Sep;111(37):13475–13480. Available from: http://www.pnas.org/content/111/37/13475. doi: 10.1073/pnas.140666311125097264
11. Siliciano JD, Siliciano RF, Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods in Molecular Biology. 2005;304:3–15. 16061962
12. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathog. 2013Feb;9(2):e1003174. doi: 10.1371/journal.ppat.100317423459007
13. Bruner KM, Hosmane NN, Siliciano RF, Towards an HIV-1 cure: measuring the latent reservoir. Trends in Microbiology. 2015Jan;23(4):192–203. Available from: http://www.cell.com/article/S0966842X1500027X/abstract. doi: 10.1016/j.tim.2015.01.01325747663
14. Rosenbloom DI, Elliott O, Hill AL, Henrich T, Siliciano J, Siliciano R, Designing and interpreting limiting dilution assays for estimating the size of HIV reservoirs. In preparation. 2015;.
15. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003Jun;9(6):727–728. doi: 10.1038/nm88012754504
16. Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. Journal of Infectious Diseases. 2015Apr;p. jiv218. Available from: http://jid.oxfordjournals.org/content/early/2015/04/15/infdis.jiv218. doi: 10.1093/infdis/jiv21825877550
17. Luo R, Piovoso MJ, Martinez-Picado J, Zurakowski R, HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics. PLoS ONE. 2012Jul;7(7):e40198. doi: 10.1371/journal.pone.004019822815727
18. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 2000;14(4):397.
19. Singh A, Razooky B, Cox CD, Simpson ML, Weinberger LS, Transcriptional bursting from the HIV-1 promoter is a significant source of stochastic noise in HIV-1 gene expression. Biophysical journal. 2010;98(8):L32–4. doi: 10.1016/j.bpj.2010.03.00120409455
20. Bui JK, Mellors JW, Cillo AR, HIV-1 virion production from single inducible proviruses following T-cell activation ex vivo. Journal of Virology. 2015Nov;p. JVI.02520–15. Available from: http://jvi.asm.org.ezp-prod1.hul.harvard.edu/content/early/2015/11/05/JVI.02520-15. doi: 10.1128/JVI.02520-1526559835
21. Pennings PS, Standing Genetic Variation and the Evolution of Drug Resistance in HIV. PLoS Comput Biol. 2012Jun;8(6):e1002527. doi: 10.1371/journal.pcbi.100252722685388
22. Pennings PS, Kryazhimskiy S, Wakeley J, Loss and recovery of genetic diversity in adapting populations of HIV. PLoS Genetics. 2014;10(1):e1004000. doi: 10.1371/journal.pgen.100400024465214
23. Rouzine IM, Coffin JM, Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci USA. 1999;96(19):10758–10763. doi: 10.1073/pnas.96.19.1075810485899
24. Rouzine IM, Razooky BS, Weinberger LS, Stochastic variability in HIV affects viral eradication. Proceedings of the National Academy of Sciences. 2014Sep;111(37):13251–13252. Available from: http://www.pnas.org/content/111/37/13251. doi: 10.1073/pnas.1413362111
25. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, et al. Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant. New England Journal of Medicine. 2013;369(19):1828–1835. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1302976. doi: 10.1056/NEJMoa130297624152233
26. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA. 2012Jun;109(24):9523–9528. doi: 10.1073/pnas.112024810922645358
27. Hütter G, Nowak D, Mossner M, Ganepola S, Möig A, Allers K, et al. Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. New England Journal of Medicine. 2009;360(7):692–698. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa0802905. doi: 10.1056/NEJMoa080290519213682
28. Henrich TJ, Hanhauser E, Sirignano M, Davis B, Lee TH, Keating S, et al. In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoietic stem cell transplantation. In: International AIDS Society. vol. WELB-05. Kuala Lumpur, Malasia: International AIDS Society; 2013. Available from: http://pag.ias2013.org/Abstracts.aspx?AID=3165.
29. Henrich TJ, Challenges and strategies towards a functional cure: how low do you need to go? In: HIV Persistence during Therapy. Miami, Florida: Informed Horizons, LLC; 2013. Available from: http://pag.ias2013.org/Abstracts.aspx?AID=3165.
30. Zou S, Glynn S, Kuritzkes D, Shah M, Cook N, Berliner N, et al. Hematopoietic cell transplantation and HIV cure: where we are and what next?Blood. 2013Oct;122(18):3111–3115. Available from: http://bloodjournal.hematologylibrary.org/content/122/18/3111. doi: 10.1182/blood-2013-07-51831624009230
31. Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ, et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. Journal of Acquired Immune Deficiency Syndromes. 2013Aug;63(4):438–441. doi: 10.1097/QAI.0b013e31828e616323493152
32. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure. Cell. 2013Oct;155(3):540–551. doi: 10.1016/j.cell.2013.09.02024243014
33. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature medicine. 2008;14(7):762766. doi: 10.1038/nm1777
34. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nature Medicine. 2012Feb;18(3):446–451. Available from: http://www.nature.com/nm/journal/v18/n3/full/nm.2649.html. doi: 10.1038/nm.264922344296
35. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis. 2004Apr;189(8):1452–1465. doi: 10.1086/38248815073683
36. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Böni J, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA. 2008Oct;105(43):16725–16730. doi: 10.1073/pnas.080419210518936487
37. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial. PLoS Med. 2010Aug;7(8):e1000321. doi: 10.1371/journal.pmed.100032120711481
38. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2009;106(23):9403. doi: 10.1073/pnas.090310710619470482
39. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA, Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nature Medicine. 2012;18(9):1378–1385. Available from: http://www.nature.com.ezp-prod1.hul.harvard.edu/nm/journal/v18/n9/full/nm.2892.html. doi: 10.1038/nm.289222941277
40. Luo R, Cardozo EF, Piovoso MJ, Wu H, Buzon MJ, Martinez-Picado J, et al. Modelling HIV-1 2-LTR dynamics following raltegravir intensification. Journal of The Royal Society Interface. 2013Jul;10(84). Available from: http://rsif.royalsocietypublishing.org/content/10/84/20130186. doi: 10.1098/rsif.2013.0186
41. Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF, Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART. PLoS Pathog. 2007;3(8):e122. Available from: http://dx.plos.org/10.1371/journal.ppat.0030122. doi: 10.1371/journal.ppat.003012217784786
42. Davey RT, JrBhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. 1999;96(26):1510915114.
43. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS, Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection. Journal of Virology. 2010Jun;84(12):6096–6102. Available from: http://jvi.asm.org/content/84/12/6096.abstract. doi: 10.1128/JVI.00127-1020357090
44. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2008May;105(21):7552–7557. PMC2387184. Available from: http://www.pubmedcentral.nih.gov.ezp-prod1.hul.harvard.edu/articlerender.fcgi?artid=2387184. doi: 10.1073/pnas.080220310518490657
45. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80(13):6441. doi: 10.1128/JVI.00591-0616775332
46. Wagner TA, McKernan JL, Tobin NH, Tapia KA, Mullins JI, Frenkel LM, An Increasing Proportion of Monotypic HIV-1 DNA Sequences during Antiretroviral Treatment Suggests Proliferation of HIV-Infected Cells. Journal of Virology. 2013Feb;87(3):1770–1778. Available from: http://jvi.asm.org/content/87/3/1770. doi: 10.1128/JVI.01985-1223175380
47. Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O’Shea A, et al. Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy. PLoS Pathog. 2014Mar;10(3):e1004010. doi: 10.1371/journal.ppat.100401024651464
48. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014Jul;345(6193):179–183. Available from: http://www.sciencemag.org/content/345/6193/179. doi: 10.1126/science.125419424968937
49. Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, et al. HIV-1 Integration Landscape during Latent and Active Infection. Cell. 2015Jan;160(3):420–432. doi: 10.1016/j.cell.2015.01.02025635456
50. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci USA. 2015Mar;112(10):E1126–E1134. Available from: http://www.pnas.org/content/112/10/E1126. doi: 10.1073/pnas.141492611225713386
51. Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, et al. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5–8 Days Implications for HIV Remission. PLoS Pathog. 2015Jul;11(7):e1005000. doi: 10.1371/journal.ppat.100500026133551
52. Hill AL, Rosenbloom DIS, Siliciano JD, Siliciano RF, Insufficient evidence for rare activation of latent HIV in the absence of reservoir-reducing interventions. PLoS Pathogens. 2016;In press (Formal Comment).
53. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV, Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 2005;122(2):169–182. doi: 10.1016/j.cell.2005.06.00616051143
54. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893–900. doi: 10.1038/nm.197219543283
55. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345(6196):570–573. Available from: http://science.sciencemag.org/content/345/6196/570.short. doi: 10.1126/science.125630425011556
56. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016Feb;530(7588):51–56. Available from: http://www.nature.com/nature/journal/v530/n7588/full/nature16933.html. doi: 10.1038/nature1693326814962
57. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. Journal of Infectious Diseases. 2000;182(6):1636–1642. Available from: http://jid.oxfordjournals.org/content/182/6/1636.short. doi: 10.1086/31761511069234
58. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS pathogens. 2013Mar;9(3):e1003211. doi: 10.1371/journal.ppat.100321123516360
59. Conway JM, Perelson AS, Post-treatment control of HIV infection. Proceedings of the National Academy of Sciences. 2015Apr;112(17):5467–5472. Available from: http://www.pnas.org/content/112/17/5467. doi: 10.1073/pnas.1419162112
60. Nowak MA, May RMC, Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, USA; 2000.